Eli Lilly Expected to Beat Q2 Revenue Forecasts on Weight-Loss Drugs, RBC Says
() -- Eli Lilly (LLY) is expected to deliver Q2 revenue slightly above consensus on stronger-than-anticipated sales of Mounjaro and Zepbound, RBC Capital Markets said Wednesday in a report. RBC forecasts Q2 revenue of about $20.7 billion, ahead of the $20.5 billion consensus estimate, driven by 5% to 6% beats for the d